Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study

David Niederseer, Sabine A M Richter, Daniel Neunhäuserer, Bernd Lamprecht, A (Sonia) Buist, Michael Studnicka, Josef Niebauer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Evidence-based medicine promotes the current best evidence from clinical trials to guide decisions for individual patients. We assessed whether chronic obstructive pulmonary disease (COPD) patients included in exercise training studies and pharmacologic trials match those from a non-selected COPD target population sample. Methods: Exercise training studies were identified in a literature search. Towards a Revolution in COPD Health (TORCH) and Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) were chosen to represent pharmacologic trials. Burden of Obstructive Lung Disease (BOLD) data were used to characterize target COPD population (BOLD target), defined as the presence of dyspnea (modified Medical Research Council ≥2) and non-reversible airway obstruction (post-bronchodilator FEV1/FVC ≤0.7 and FEV1% predicted ≤70 %). Results: Overall 240 exercise training studies with 13,901, TORCH and UPLIFT with 12,105, and BOLD with 16,218 participants were evaluated. Males were overrepresented in exercise training studies (67.5 %) and pharmacologic trials (TORCH 75.8 %; UPLIFT 74.6 %), whereas in BOLD target 55.8 % were males (p <0.001). In exercise training studies, 7.2 % were never-smokers, 0.0 % in TORCH and UPLIFT, but 36.0 % in BOLD target (p <0.001). Subjects with cardiac comorbidity were excluded from 75.4 % of exercise training studies, entirely from TORCH and UPLIFT, but comprised 24.5 % of BOLD target. Conclusions: COPD patients recruited in exercise training studies and in pharmacologic trials differ from target population of symptomatic COPD. Females, never-smokers, and patients with cardiac comorbidities are more likely excluded from the clinical trials.

Original languageEnglish (US)
Pages (from-to)801-808
Number of pages8
JournalSleep and Breathing
Volume19
Issue number3
DOIs
StatePublished - Nov 27 2014

Fingerprint

Chronic Obstructive Pulmonary Disease
Obstructive Lung Diseases
Clinical Trials
Exercise
Population
Health
Health Services Needs and Demand
Comorbidity
Evidence-Based Medicine
Bronchodilator Agents
Airway Obstruction
Dyspnea
Biomedical Research
Tiotropium Bromide

Keywords

  • Exercise training
  • External validity
  • Rehabilitation

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Clinical Neurology

Cite this

Niederseer, D., Richter, S. A. M., Neunhäuserer, D., Lamprecht, B., Buist, A. S., Studnicka, M., & Niebauer, J. (2014). Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study. Sleep and Breathing, 19(3), 801-808. https://doi.org/10.1007/s11325-014-1087-5

Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study. / Niederseer, David; Richter, Sabine A M; Neunhäuserer, Daniel; Lamprecht, Bernd; Buist, A (Sonia); Studnicka, Michael; Niebauer, Josef.

In: Sleep and Breathing, Vol. 19, No. 3, 27.11.2014, p. 801-808.

Research output: Contribution to journalArticle

Niederseer, D, Richter, SAM, Neunhäuserer, D, Lamprecht, B, Buist, AS, Studnicka, M & Niebauer, J 2014, 'Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study', Sleep and Breathing, vol. 19, no. 3, pp. 801-808. https://doi.org/10.1007/s11325-014-1087-5
Niederseer, David ; Richter, Sabine A M ; Neunhäuserer, Daniel ; Lamprecht, Bernd ; Buist, A (Sonia) ; Studnicka, Michael ; Niebauer, Josef. / Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study. In: Sleep and Breathing. 2014 ; Vol. 19, No. 3. pp. 801-808.
@article{d58ff41363a145c7a107060ed3122f27,
title = "Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study",
abstract = "Purpose: Evidence-based medicine promotes the current best evidence from clinical trials to guide decisions for individual patients. We assessed whether chronic obstructive pulmonary disease (COPD) patients included in exercise training studies and pharmacologic trials match those from a non-selected COPD target population sample. Methods: Exercise training studies were identified in a literature search. Towards a Revolution in COPD Health (TORCH) and Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) were chosen to represent pharmacologic trials. Burden of Obstructive Lung Disease (BOLD) data were used to characterize target COPD population (BOLD target), defined as the presence of dyspnea (modified Medical Research Council ≥2) and non-reversible airway obstruction (post-bronchodilator FEV1/FVC ≤0.7 and FEV1{\%} predicted ≤70 {\%}). Results: Overall 240 exercise training studies with 13,901, TORCH and UPLIFT with 12,105, and BOLD with 16,218 participants were evaluated. Males were overrepresented in exercise training studies (67.5 {\%}) and pharmacologic trials (TORCH 75.8 {\%}; UPLIFT 74.6 {\%}), whereas in BOLD target 55.8 {\%} were males (p <0.001). In exercise training studies, 7.2 {\%} were never-smokers, 0.0 {\%} in TORCH and UPLIFT, but 36.0 {\%} in BOLD target (p <0.001). Subjects with cardiac comorbidity were excluded from 75.4 {\%} of exercise training studies, entirely from TORCH and UPLIFT, but comprised 24.5 {\%} of BOLD target. Conclusions: COPD patients recruited in exercise training studies and in pharmacologic trials differ from target population of symptomatic COPD. Females, never-smokers, and patients with cardiac comorbidities are more likely excluded from the clinical trials.",
keywords = "Exercise training, External validity, Rehabilitation",
author = "David Niederseer and Richter, {Sabine A M} and Daniel Neunh{\"a}userer and Bernd Lamprecht and Buist, {A (Sonia)} and Michael Studnicka and Josef Niebauer",
year = "2014",
month = "11",
day = "27",
doi = "10.1007/s11325-014-1087-5",
language = "English (US)",
volume = "19",
pages = "801--808",
journal = "Sleep and Breathing",
issn = "1520-9512",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study

AU - Niederseer, David

AU - Richter, Sabine A M

AU - Neunhäuserer, Daniel

AU - Lamprecht, Bernd

AU - Buist, A (Sonia)

AU - Studnicka, Michael

AU - Niebauer, Josef

PY - 2014/11/27

Y1 - 2014/11/27

N2 - Purpose: Evidence-based medicine promotes the current best evidence from clinical trials to guide decisions for individual patients. We assessed whether chronic obstructive pulmonary disease (COPD) patients included in exercise training studies and pharmacologic trials match those from a non-selected COPD target population sample. Methods: Exercise training studies were identified in a literature search. Towards a Revolution in COPD Health (TORCH) and Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) were chosen to represent pharmacologic trials. Burden of Obstructive Lung Disease (BOLD) data were used to characterize target COPD population (BOLD target), defined as the presence of dyspnea (modified Medical Research Council ≥2) and non-reversible airway obstruction (post-bronchodilator FEV1/FVC ≤0.7 and FEV1% predicted ≤70 %). Results: Overall 240 exercise training studies with 13,901, TORCH and UPLIFT with 12,105, and BOLD with 16,218 participants were evaluated. Males were overrepresented in exercise training studies (67.5 %) and pharmacologic trials (TORCH 75.8 %; UPLIFT 74.6 %), whereas in BOLD target 55.8 % were males (p <0.001). In exercise training studies, 7.2 % were never-smokers, 0.0 % in TORCH and UPLIFT, but 36.0 % in BOLD target (p <0.001). Subjects with cardiac comorbidity were excluded from 75.4 % of exercise training studies, entirely from TORCH and UPLIFT, but comprised 24.5 % of BOLD target. Conclusions: COPD patients recruited in exercise training studies and in pharmacologic trials differ from target population of symptomatic COPD. Females, never-smokers, and patients with cardiac comorbidities are more likely excluded from the clinical trials.

AB - Purpose: Evidence-based medicine promotes the current best evidence from clinical trials to guide decisions for individual patients. We assessed whether chronic obstructive pulmonary disease (COPD) patients included in exercise training studies and pharmacologic trials match those from a non-selected COPD target population sample. Methods: Exercise training studies were identified in a literature search. Towards a Revolution in COPD Health (TORCH) and Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) were chosen to represent pharmacologic trials. Burden of Obstructive Lung Disease (BOLD) data were used to characterize target COPD population (BOLD target), defined as the presence of dyspnea (modified Medical Research Council ≥2) and non-reversible airway obstruction (post-bronchodilator FEV1/FVC ≤0.7 and FEV1% predicted ≤70 %). Results: Overall 240 exercise training studies with 13,901, TORCH and UPLIFT with 12,105, and BOLD with 16,218 participants were evaluated. Males were overrepresented in exercise training studies (67.5 %) and pharmacologic trials (TORCH 75.8 %; UPLIFT 74.6 %), whereas in BOLD target 55.8 % were males (p <0.001). In exercise training studies, 7.2 % were never-smokers, 0.0 % in TORCH and UPLIFT, but 36.0 % in BOLD target (p <0.001). Subjects with cardiac comorbidity were excluded from 75.4 % of exercise training studies, entirely from TORCH and UPLIFT, but comprised 24.5 % of BOLD target. Conclusions: COPD patients recruited in exercise training studies and in pharmacologic trials differ from target population of symptomatic COPD. Females, never-smokers, and patients with cardiac comorbidities are more likely excluded from the clinical trials.

KW - Exercise training

KW - External validity

KW - Rehabilitation

UR - http://www.scopus.com/inward/record.url?scp=84940956500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940956500&partnerID=8YFLogxK

U2 - 10.1007/s11325-014-1087-5

DO - 10.1007/s11325-014-1087-5

M3 - Article

VL - 19

SP - 801

EP - 808

JO - Sleep and Breathing

JF - Sleep and Breathing

SN - 1520-9512

IS - 3

ER -